WHO Sets First Integrated Obesity-Care Guidance for Children and Adolescents

The World Health Organization has issued its first global clinical guidance focused on treating obesity in children and adolescents. Published October 7, 2026, the recommendations put sustained, person-centred care at the centre and distinguish clearly between children under 10 and adolescents. They are global clinical guidance—not a Canadian drug approval, prescribing authorization or coverage decision. The recommendations are set out in separate guidance for children and guidance for adolescents.

Two age groups, one integrated-care approach

WHO’s documents cover children aged 29 days to under 10 years and adolescents aged 10–19. Both emphasize structured care that combines nutrition support, physical activity and behaviour-change strategies. Programs may be delivered individually or as part of broader services; WHO also conditionally supports digital interventions when a parent or caregiver supervises their use. The aim is to support health and wellbeing through continuing care, not to reduce treatment to a target number on a scale.

The recommendations are based on systematic evidence reviews and consider more than efficacy alone, including potential harms, equity, feasibility and the perspectives of young people and caregivers. WHO reports that about 170 million people aged 5–19 were living with obesity in 2024. That population estimate provides context, but does not substitute for an individual assessment of growth, development, health conditions, family circumstances or the young person’s own priorities.

Medication recommendations differ by age

For children aged 0–9, WHO does not recommend weight-loss medicines, bariatric surgery or weight-loss devices. For adolescents aged 10–19, the organization says approved pharmacotherapy may be considered only when a supervised, multimodal lifestyle program has not achieved the desired results. Medication remains part of continuing comprehensive care; it is not presented as a replacement for nutrition, activity, behavioural or family support. Bariatric surgery is a separate option that may be considered for adolescents with severe obesity under strict conditions.

This age distinction is important when families encounter headlines about obesity medicines. A recommendation to consider treatment for some adolescents is not a recommendation for every young person, a product-specific endorsement or permission to use a medicine outside its approved indication. Clinical decisions still require individual assessment, discussion of benefits and risks, and appropriate monitoring.

How the guidance fits with Canadian practice

Canada already has a product-specific adolescent indication for semaglutide (Wegovy). Health Canada’s Notice of Compliance applies to selected patients aged 12 to under 18 with obesity, a body weight above 60 kg and an inadequate response to reduced-calorie diet and increased physical activity alone. That authorization predates the WHO guidance. The WHO publication does not expand the Canadian indication, change a product monograph, establish provincial public coverage or create new pharmacist prescribing authority. Pharmacists should check the current Canadian product label, provincial rules and local coverage criteria separately.

WHO’s framework and Health Canada’s authorization serve different purposes: one describes a global care pathway; the other defines the conditions under which a particular product is authorized in Canada. For pharmacy teams, the practical value of the new guidance is its emphasis on integrated, respectful care and its explicit separation of child and adolescent recommendations.

Practice guidance for pharmacists

• When asked about an obesity medicine, establish the patient’s age and clinical context, then verify the current Canadian product monograph rather than relying on a headline about WHO guidance.
• Explain that WHO places medication for adolescents within supervised, multimodal care and does not recommend weight-loss medicines for children under 10.
• For an adolescent who may meet a product’s approved indication, coordinate with the prescriber about assessment, shared decision-making, monitoring, adverse effects and follow-up.
• Check provincial coverage and prior-authorization rules independently; WHO’s recommendations do not change reimbursement.
• Use non-stigmatizing language, ask permission before discussing weight, and consider the young person’s preferences, mental health and social context.
• Refer questions about diagnosis, eligibility or complications to the appropriate clinician; do not infer treatment eligibility from weight alone.

What to watch next

The guidelines are intended to inform adaptation by countries and health systems. Canadian pharmacy teams should watch for local professional guidance, product-label changes and provincial coverage decisions. Until those authorities change, the WHO documents are best understood as a framework for integrated care—not a change to Canadian prescribing rules.

Primary sources

• WHO announcement, October 7, 2026
• WHO guideline: integrated management of obesity in children under 10
• WHO guideline: integrated management of obesity in adolescents
• Health Canada Notice of Compliance for Wegovy